-
What to Expect from Biomarin Pharmaceutical's Earnings
24 Oct 2025 15:15 GMT
… and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement … achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively …
-
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
13 Oct 2025 05:22 GMT
… -ever therapy for the rare, genetic disorder characterized by short stature … analogs,” Tsai said.
Of course, BioMarin, currently the undisputed achondroplasia leader … instance, BioMarin has a late-stage program for hypochondroplasia, a genetic disorder …
-
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane Parasail - ResearchAndMarkets.com
06 Oct 2025 19:24 GMT
… of diagnostic technologies and genetic testing is fostering earlier … in regions with higher genetic predispositions and increased access … pharmaceutical companies such as BioMarin Pharmaceutical Inc., Oxyrane, … Therapies
5.2.3 BioMarin Pharmaceutical Inc.
5.2 …
-
Gene Therapy For Inherited Genetic Disorders Industry Report: Competitive Landscape and Future Prospects
11 Sep 2025 00:30 GMT
… increasing number of inherited genetic disorders, escalating investments and … gene therapy for inherited genetic disorders. Personalized medicine is … • Vertex Pharmaceuticals Incorporated
• Genentech
• Biomarin Pharmaceutical Inc
• Sarepta Therapeutics Inc …
-
Biomarin Shares New Data Reinforcing Its Leadership In Bone Health At The American Society For Bone And Mineral Research Annual Meeting
08 Sep 2025 16:58 GMT
… genetic condition that affects blood vessels, soft tissues and bones. BioMarin … development, BioMarin seeks to unleash the full potential of genetic science by … information, future events or otherwise.
BioMarin®, BioMarin RareConnections® and VOXZOGO® are …
-
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
06 Sep 2025 15:29 GMT
… including Boxed Warning.
About BioMarin
BioMarin is a global biotechnology company … development, BioMarin seeks to unleash the full potential of genetic science … information, future events or otherwise.
BioMarin®, BioMarin RareConnections® and PALYNZIQ® are …
-
What's Next: Biomarin Pharmaceutical's Earnings Preview
01 Aug 2025 15:35 GMT
… commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme … (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively … operational capacity.
Revenue Growth: Biomarin Pharmaceutical's remarkable …
-
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
01 Aug 2025 13:20 GMT
… around the world."
About BioMarin
BioMarin is a global biotechnology company … -to-treat genetic conditions. To learn more, please visit www.biomarin.com … the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, …
-
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating
24 Jun 2025 08:14 GMT
… . Barclays Initiates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) A pharmaceutical … -type natriuretic peptide. According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s … ) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease …
-
Jim Cramer on BioMarin: “I Don’t Think It Works Now”
16 Jun 2025 18:20 GMT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is … , Cramer remarked:
“You know what, BioMarin, I am getting tired of … works now.” Jim Cramer on BioMarin: “I Don't Think … . BioMarin (NASDAQ:BMRN) is a biotechnology company focused on turning genetic research …
About
© 1995-2025